Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens of millions” of renminbi in an angel financing round, solely led by BGI Co-Win. The proceeds will be used for technology upgrades, team building, testing business development, and laboratory platform automation construction.
Company Background and Focus
Founded in 2021, Waker Bio is focused on providing carrier insertion mutation safety evaluation for cell and gene therapy drugs. The company has provided ISA testing work for all gene therapy products that have been successfully listed overseas, including the world’s first gene therapy product and the first CAR-T product, and is the maker of industry specifications, according to the source.
Future Prospects and Strategic Use of Funds
The angel financing round positions Waker Bioscience to further enhance its capabilities in integration site analysis. By investing in technology upgrades, team building, and laboratory platform automation, Waker aims to solidify its position as a leader in the ISA field, addressing significant unmet medical needs and improving patient outcomes through advanced safety evaluations.-Fineline Info & Tech
